Florida's HIV Care Crisis Spurs Telehealth Lifeline

SAN JUAN, PR – April 06, 2026 – As thousands of Floridians living with HIV face an uncertain future due to drastic state-level cuts to a critical medication program, a private telehealth company has announced it will step in to bridge the gap. MISTR, a platform known for providing online PrEP, confirmed today it will offer free, long-term HIV care and insurance premium support to anyone affected by recent changes to Florida’s AIDS Drug Assistance Program (ADAP).

The move highlights a burgeoning crisis in public health funding and spotlights the growing role of technology-driven platforms in providing a safety net where government programs are faltering. The intervention comes in response to policy shifts in Florida that advocates have labeled "life-endangering" and "fiscally reckless."

The Human Cost of Policy Shifts

Effective March 1, 2026, the Florida Department of Health implemented severe changes to its ADAP, a program that has long been a lifeline for low-income individuals with HIV. The state eliminated assistance for health insurance premiums and dramatically lowered the income eligibility for uninsured individuals to receive medication, dropping the threshold from 400% of the federal poverty level (FPL) to just 130%. For a single person, this represents a drop in annual income eligibility from approximately $64,000 to just $21,000.

Furthermore, the state removed Biktarvy, the most widely prescribed HIV treatment in the United States, from its approved drug list, forcing patients to either switch medications against their doctor's advice or find another way to pay for it. A 30-day supply of Biktarvy can cost between $5,000 and $6,000, a sum that is far out of reach for most individuals without comprehensive coverage.

Advocacy groups estimate that as many as 16,000 of the program's 32,000 clients could lose their coverage, creating a public health emergency. "It has been an emotional roller coaster," said one long-time patient who has relied on ADAP for years to stay healthy and prevent transmission to her family. The stress and instability caused by the sudden loss of coverage, she noted, undermines decades of progress in HIV treatment and care.

While the Florida legislature recently allocated $30.9 million in temporary bridge funding, the measure is seen as a temporary fix. It does not restore the crucial insurance premium assistance and fails to add Biktarvy back to the formulary, leaving the core problems unresolved for thousands of patients.

A Digital Safety Net Emerges

In this climate of uncertainty, MISTR’s announcement provides a tangible alternative for those falling through the cracks. The company has pledged to cover affected Florida patients, ensuring continuity of care at little to no cost.

“MISTR was built to remove barriers to care,” said Tristan Schukraft, Founder and CEO of MISTR, in the company’s press release. “If you’re in Florida and you’ve lost access to coverage, we will make sure you stay on your medication.”

The platform’s model is designed for accessibility. Patients enroll online and consult with a licensed HIV specialist via video every six months. MISTR coordinates required lab work at one of over 2,200 partner locations and manages the entire insurance and prescription process. For patients impacted by the ADAP changes, the company will help them enroll in insurance plans that cover their prescribed medications, including Biktarvy, and will provide up to $250 per month in premium assistance as long as they remain in care.

This end-to-end management system—handling plan selection, enrollment, and prescription fulfillment without requiring clinic visits or complex paperwork—is specifically designed to address the logistical and financial hurdles that now confront Florida’s HIV community.

A System Under Strain

Florida's situation is a stark example of a nationwide issue. ADAPs across the country are under immense pressure due to a combination of flat federal funding and rising costs for both medications and insurance premiums. According to the National Alliance of State and Territorial AIDS Directors (NASTAD), federal ADAP funding has remained at $900 million for over a decade, a figure that represents a 31% decline when adjusted for inflation.

As of February 2026, at least 23 states were reportedly considering or had already implemented cost-containment measures for their ADAP programs. These measures range from reducing income eligibility and restricting drug formularies, as seen in Florida, to implementing spending caps or even reintroducing waiting lists, which had been largely eliminated over a decade ago.

Advocacy groups like AIDS United and IAPAC have strongly condemned these cuts, arguing they are not only dangerous to patients but also economically shortsighted. Interrupting HIV treatment can lead to viral rebound, the development of drug resistance, and worsened health outcomes. It also increases the risk of new HIV transmissions. A Johns Hopkins study projected that if 16,000 Floridians lose ADAP coverage, new HIV infections in the state could rise by 28% through 2030, leading to long-term healthcare costs that would far exceed the initial savings from the cuts.

The Future of HIV Care Delivery?

The crisis in Florida and the corresponding rise of telehealth solutions like MISTR may signal a paradigm shift in how chronic diseases are managed. While traditional clinic-based care, often supported by the federal Ryan White Program, remains the bedrock of HIV treatment, telehealth platforms offer a level of agility and scalability that public health systems can struggle to match, especially in a crisis.

By leveraging technology to connect patients with specialists across the country and by navigating the complex insurance landscape on behalf of the patient, these platforms can overcome geographical and bureaucratic barriers. MISTR’s commitment to serving both insured and uninsured patients, and its willingness to directly subsidize insurance premiums, sets a new precedent for private sector involvement in public health crises.

This intervention provides a critical, immediate solution for Floridians. It also raises larger questions about the long-term sustainability of relying on a patchwork of public programs and private entities to ensure access to life-saving medication. For now, for thousands of anxious patients, it is a welcome and necessary lifeline.

“We have the science and the tools to end HIV,” Schukraft added. “The challenge is access. When systems create gaps, people still need care. MISTR was built to close those gaps, and we’re ready to do that in Florida and anywhere patients are at risk of losing coverage.”